Moderna (NASDAQ: MRNA) shares reversed an early 9.6% premarket gain on Friday, despite the vaccine maker reporting better-than-expected third-quarter earnings and raising its 2026 revenue growth forecast to 15%–25%, from a previous outlook of up to 10%. The stock initially climbed to $264.79 after the earnings announcement but later fell to $239.85, down 0.67% from Thursday’s close of $241.46.
Visit Website
.jpg)
